PMV Pharmaceuticals
PMVP· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock -17.2% in FY2025
David H. Mack, Ph.D. is the CEO of PMV Pharmaceuticals and was paid $1.7M in FY2025 (Dec), down 65%.
Pay$100 in the stock at the end of FY21 → $5
Executives3
See all- 1David H. Mack, Ph.D.President, Chief Executive Officer and DirectorFY2025
- 2Deepika Jalota, Pharm.D.Chief Development OfficerFY2025
- 3Robert TicktinGeneral Counsel & Chief Operating OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allPMV Pharmaceuticals paid its 3 named executives $3.5M in total in FY2025 (Dec). CEO David H. Mack, Ph.D. was paid $1.7M of that.
| Name | |||
|---|---|---|---|
| David H. Mack, Ph.D.President, Chief Executive Officer and Director | |||
| Deepika Jalota, Pharm.D.Chief Development Officer | |||
| Robert TicktinGeneral Counsel & Chief Operating Officer | Not disclosed | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for PMV Pharmaceuticals. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board6
See all- Richard Heyman, Ph.D.Chair · 5 yr on the boardIndependentAudit, Compensation (Chair), Nominating and Corporate Governance—Paid as an executive
- Arnold Levine, Ph.D.Director · 12 yr on the boardIndependent—Paid as an executive
- David H. Mack, Ph.D.Director · 12 yr on the boardNot independent—Paid as an executive
- Laurie StelzerDirector · 5 yr on the boardIndependentAudit (Chair), Compensation—Paid as an executive
- Charles M. Baum, M.D., Ph.D.Director · 4 yr on the boardIndependentCompensation, Nominating and Corporate Governance—Paid as an executive
- Kirsten FlowersDirector · 3 yr on the boardIndependentAudit—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 22, 2026 | FY2025 |
| Annual report | 10-K | Mar 6, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 25, 2025 | FY2024 |
| Annual report | 10-K | Mar 3, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 24, 2024 | FY2023 |
| Annual report | 10-K | Feb 29, 2024 | FY2023 |
